Acrux Limited (ASX:ACR)

Market Cap	5.75M
Revenue (ttm)	1.19M
Net Income (ttm)	-5.95M
Shares Out	410.61M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	845,491
Average Volume	138,125
Open	0.0140
Previous Close	0.0140
Day's Range	0.0140 - 0.0140
52-Week Range	0.0120 - 0.0340
Beta	0.93
RSI	47.98
Earnings Date	Feb 26, 2026

About Acrux

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream. It is also involved in the development of Efinaconazo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 43
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ACR

Financial Performance

In 2025, Acrux's revenue was 1.19 million, a decrease of -76.63% compared to the previous year's 5.09 million. Losses were -5.95 million, 2.50% more than in 2024.